



NORD[®]
National Organization for Rare Disorders

IAMRARE Registry & Patient-Centered Research Program Overview

Vanessa Boulanger, Director of Research

Presentation for the Advisory Committee on Heritable Disorders in Newborns and Children, March 22 2019


Alone we are rare. Together we are strong.[®]



Overview

- Brief Introduction to NORD
- IAMRARE Registry Program: Overview of Growth and Impact
- Registry Partnerships and Models of Engagement
- Opportunities to Engage: Research Studies and Data Resources





Introduction to NORD



rarediseases.org

NORD, an independent nonprofit, is leading the fight to improve the lives of **rare disease patients and families**.

We do this by supporting patients and organizations, accelerating research, providing education, disseminating information and driving public policy.



rarediseases.org

Pillars of NORD

Policy & Advocacy

- Federal and State Policy
- Regulatory Affairs
- Rare Action Network® Grassroots advocacy coalition present in all 50 states
- Advocate training workshops

Tracking
> 150 bills

Hosted over
200
legislative
meetings

Servicing
>7,000
patients/yr

Fielding
114k phone
calls/yr

Research

- Research grants for translational or clinical studies
- IAMRARE® registry platform and natural history study development program
- Original research and publications

Over 30
Registry
Partnerships

2 FDA
Approved
Products

Patient Services

- Premium, copay and coinsurance support
- Diagnostic and genetic testing
- Ancillary services
- Clinical trial recruitment and travel & lodging
- Emergency relief programs

Education

- Patient and family education
- Medical professional education
- Annual Rare Diseases & Orphan Products Breakthrough Summit
- Rare disease mentorship & workshops for patient advocacy groups

1,200+ rare
disease
reports

Summit
Draws 700+
Attendees




IAMRARE Registry Program




rarediseases.org

History of the IAMRARE Program



IAMRARE Program



- IAMRARE™ Platform
 - Training, User Guides
- Study Resources
 - Core Survey Library
 - Custom Survey Support
 - Templates (e.g. consent, marketing)
 - IRB Partnership
- IAMRARE™ Community
 - Portal, Meetings, Webinars, Newsletters, Videos



IAMRARE Registry Community Members



- Arachnoiditis
- Autoimmune Polyglandular Syndrome type 1 (APS-1, APECED)
- Cat Eye Syndrome
- Congenital Central Hypoventilation Syndrome (CCHS)
- Congenital Hyperinsulinism (CHI)
- Dercum's Disease
- Desmoid Tumors
- Fibrous Dysplasia and McCune–Albright Syndrome (FD/MAS)
- Galactosemia
- Idiopathic Thrombocytopenic Purpura (ITP)
- Leukodystrophy
- Moyamoya
- Necrotizing Enterocolitis (NEC)
- Opsoclonus Myoclonus Syndrome (OMS)
- Organic Acidemia
- Pemphigus and Pemphigoid
- Phenylketonuria (PKU)
- Prader-Willi Syndrome
- SMARD 1
- SPG47
- Syngap1
- Syringomyelia & Chiari
- Tyrosinemia Type 1
- Undiagnosed
- Von Hippel Lindau
- 17q12




Example question sets - PKU

- About participant - demographics
- Diagnosis – date and type, NBS, PAH mutations, family relationships/history
- Treatment – age at PKU diet, diet start/stop, medical foods, adherence, Phe levels, Tyrosine levels, complete metabolic blood tests, essential fatty acids, supplement use
- Medical history –physical function and activity, vaccinations, serious illness history, neurological, dermatological, ADD/ADHD, autism, psychiatric, bone density, oral health, stress, anxiety, depression
- Insurance information and medical costs
- Education – family, educational services/assistance
- Mood - Hospital Anxiety and Depression Scale
- Maternal – pregnancy history, birth history and assessments



IAMRARE Community Snapshot


- 34 Registry Partnerships
 - Live/Development
- 8,500+ Users; 90% active
 - Respondents
 - Data Curators
 - System Administrators
- 45,000+ Survey Submissions



IAMRARE Community Impact

SYNGAP1 heterozygosity disrupts sensory processing by reducing touch-related activity within somatosensory cortex circuits

Sheldon D. Michaelson^{1,7}, Emin D. Ozkan^{1,7}, Massimiliano Aceti^{1,6}, Sabyasachi Maity¹, Nerea Llamosas¹, **Monica Weldon²**, Elisa Mizrahi¹, Thomas Vaissiere¹, Michael A. Gaffield³, Jason M. Christie³, J. Lloyd Holder Jr.⁷, Courtney A. Miller^{1,5} and Gavin Rumbaugh^{1,5*}





Partnerships and Models of Engagement



NORD
National Organization
for Rare Disorders

rarediseases.org

Partnership Models

NORD Announces Ten New Rare Disease Registries, Thanks to Multi-Year Grant from Shire

Posted by Laura Mullen

Washington, D.C., September 11, 2018—The National Organization for Rare Disorders (NORD), the leading independent nonprofit organization representing the 30 million Americans with rare diseases, has announced the addition of ten new rare disease registries, made possible through a multi-year grant award from Shire.

The Foundation for Prader-Willi Research (FPWR) and Zafgen are pleased to announce that enrollment is now open for PATH for PWS, a natural history study intended to better understand serious medical events in Prader-Willi syndrome (PWS) and evaluate how PWS-related behaviors change over time. The data from this study is intended to inform the development and clinical trial design of potential new treatments for PWS. Those interested in participating can find more information about the study and how to enroll at www.PATHforPWS.com.

Enrollment is now open for the four-year study using the [Global PWS Registry](#), which is powered by the National Organization for Rare Disorders' (NORD) IAMRARE™ Registry Program. To be eligible for the study, participants must have a confirmed diagnosis of PWS, be at least 5 years of age, live in the United States, Canada or Australia, and be enrolled or willing to enroll in the Global PWS Registry. The primary caregiver of the enrolled person with PWS must have access to the internet to enter study data and consent to being contacted by registry staff.

PATH
for PWS™
Paving the way for Advances
in Treatments & Health for PWS



NORD-TRIO HEALTH PARTNERSHIP



NORD is pleased to present, in partnership with Trio Health, new findings from the **IAMRARE™ Patient Registry Program**, in collaboration with:

The International Pemphigus and Pemphigoid Foundation, 

The National PKU Alliance,



The OMS Life Foundation



Opportunities to Engage

- As registry partners
- As data partners
- As research project collaborators

- Speak at a NORD event
- Join NORD's Scientific and Medical Advisory Committee
- Write or review rare disease reports
- And more!



NORD-FDA Patient Listening Sessions

- The [FDA “Request to Connect” portal](https://www.fda.gov/requesttoconnect) is now live: www.fda.gov/requesttoconnect
- This new portal is an opportunity for the patient and caregiver community to submit a question or request a meeting with the FDA in order to share their disease experience or better understand FDA’s regulatory work.
- Requests for the rare disease listening sessions co-hosted by NORD and the FDA can also be submitted through the portal!



Get Connected at NORD's Major Events





NORD[®]
National Organization for Rare Disorders

Vanessa Boulanger
Director of Research
National Organization for Rare Disorders (NORD)

Questions?

Email: VBoulanger@rarediseases.org or
Research@rarediseases.org

NORD homepage: <https://rarediseases.org/>

Alone we are **rare**. Together we are strong.[®]



Thank you



rarediseases.org